Contact Congress about S. 1041: Affordable Prescriptions for Patients Act

Brand-name biologic drug companies would usually have to keep some biosimilar patent lawsuits smaller. The bill caps how many patents they can press at once, with some exceptions. That could affect how fast lower-cost biosimilars can fight patent disputes and try to enter the market.

Modern Action explains legislation in plain English, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Affordable Prescriptions for Patients Act is a Senate bill waiting for floor action. The latest recorded action: Placed on Senate Legislative Calendar under General Orders. Calendar No. 44.

Latest action on S. 1041: Placed on Senate Legislative Calendar under General Orders. Calendar No. 44.

Who this affects: This bill mainly affects companies that make brand-name biologic drugs and companies trying to sell biosimilars. It could also matter to patients, insurers, and government health programs if it changes how fast lower-cost competitors can get through patent fights and reach the market.

Why this matters: Biologic drugs can be very expensive, so patent fights that delay biosimilars can affect what people and health plans pay. This bill tries to narrow some of those fights by limiting how many patents a brand company can bring at once in one case. That could make some lawsuits less sprawling and more predictable. But judges can still expand the case, and some patents are not covered by the cap, so the real effect on prices and access is still uncertain.

Key provisions in S. 1041

• Filing a biosimilar application with the Food and Drug Administration could trigger patent claims right away. That includes patents on the drug, how it is used, and how it is made.
• A brand-name biologic company would usually be limited to 20 patents in one lawsuit against a biosimilar rival. Only 10 of those can be later-issued patents from an important stage of the patent-list exchange process.
• Not every patent can count toward that 20-patent limit. The patent must cover the biologic, its uses, or its manufacturing, appear on the required patent list, and either be filed more than 4 years after approval or cover a manufacturing method the brand company does not use.
• Judges could let a brand company bring more patents in one case. The company has to ask without delay, and fairness or good cause has to support it, including when the biosimilar company fails to share required application information.
• The bill gives examples of what good cause can mean. It includes major changes to the biosimilar drug or its manufacturing process, and delays caused by the Patent Office when issuing a patent.

How Modern Action helps you take action on S. 1041

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 1041

What is S. 1041?

Brand-name biologic drug companies would usually have to keep some biosimilar patent lawsuits smaller. The bill caps how many patents they can press at once, with some exceptions. That could affect how fast lower-cost biosimilars can fight patent disputes and try to enter the market.

How do I support or oppose S. 1041?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 1041?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

Can Modern Action explain S. 1041 before I act?

Yes. Modern Action gives you a plain-English summary, current status, and action context before you send anything.